Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto11Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba Children's Hospital, Chiba, Japan...
Guardado en:
Autores principales: | Murakami M, Tomiita M, Nishimoto N |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1e49f8547c624bd8ba503e8ab47ec06d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
por: Masahiko Mihara, et al.
Publicado: (2011) -
Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz J, et al.
Publicado: (2015) -
Intra-articular corticosteroids in the treatment of juvenile idiopathic arthritis: Safety, efficacy, and features affecting outcome. A comprehensive review of the literature
por: Alisa Carman Gotte
Publicado: (2009) -
The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation
por: Townes SV, et al.
Publicado: (2012) -
Epidemiology and demographics of juvenile idiopathic arthritis in Africa and Middle East
por: Sulaiman M. Al-Mayouf, et al.
Publicado: (2021)